Dubai, UAE, 16th Mar 2019
Globalpharma, a pharmaceutical company wholly-owned by Dubai Investments PJSC and a market leader in several generic medicines, hosted a ‘Quality in Primary Care’ healthcare symposium in Dubai. The event underlined Globalpharma’s commitment to supporting healthcare professionals in the UAE and region by strengthening their knowledge and skills, part of its long-term focus on promotion Continuous Medical Education (CME).
Around 150 healthcare professionals from the UAE, Saudi Arabia and Iraq attended the interactive seminar at which 12 experts in six therapy areas addressed the audience on latest updates, trends and findings. Attendees, who were involved throughout via an interactive, multiple choice quiz component during each session, gained six CME credit hours by the Dubai Health Authority.
The six therapy areas covered by the 12 healthcare experts were: ‘Diabetic Dyslipidemia’, ‘Management of Hypertension & CVD High-Risk Patients, ‘Management of Chronic Pain & Sports Injury, ‘Updates on the Management of Urinary Tract Infections and Erectile Dysfunction,’ ‘Current Trends, Guidelines and Challenges in the Management of GERD and H-Pylori,’ and ‘Management of Allergic Rhinitis and Rhinosinusitis’.
Globalpharma is a wholly owned subsidiary of Dubai Investments. Established in 1998 and headquartered in Dubai Investments Park, Globalpharma grew to become a market leader in certain generic medicines with a strong regional footprint. Globalpharma manufactures and markets pharmaceutical products in more than 14 countries across the GCC, Middle East and neighbouring markets.
Globalpharma manufactures and commercializes pharmaceutical products under CGMP (current good manufacturing practice) conditions including antibiotics, cardiovascular, anti-ulcerants, analgesic, NSAIDs (Nonsteroidal anti-inflammatory drugs), food supplements, vitamins, anti-diabetics, respiratory products and anti-histamine formulations.